8-K: Fortress Biotech Completes Checkpoint Therapeutics Sale, Bolstering Financial Position with $28M Cash and Future Royalties

Fortress Biotech, Inc. announced the completion of the sale of its subsidiary, Checkpoint Therapeutics, Inc., to Sun Pharmaceutical Industries, Inc., receiving an initial $28 million in cash and eligibility for significant future payments.

Summary

• Fortress Biotech, Inc. (Fortress) completed the sale of its subsidiary, Checkpoint Therapeutics, Inc. (Checkpoint), to Sun Pharmaceutical Industries, Inc. (Sun Pharma) on May 30, 2025.
• As a result of the merger, Checkpoint is now a wholly-owned subsidiary of Sun Pharma and has been deconsolidated from Fortress's financial statements.
• Fortress received approximately $28.0 million in cash at closing.
• The company is eligible to receive up to an additional $4.8 million upon the achievement of a regulatory milestone associated with Contingent Value Rights (CVRs).
• Fortress is also eligible for quarterly cash payments of 2.5% of net sales of certain Checkpoint and Sun Pharma products for a specified time period, as per a previously disclosed Royalty Agreement.
• Unaudited pro forma consolidated financial statements, giving effect to the deconsolidation of Checkpoint, were included, showing the financial impact as if the sale occurred on March 31, 2025 (for balance sheet) and January 1, 2025/2024 (for statements of operations).
• The transaction resulted in a pro forma pre-tax gain on deconsolidation of $26.6 million.
• For the three months ended March 31, 2025, the pro forma net loss attributable to Fortress improved significantly to a gain of $17.131 million, compared to a reported loss of $10.584 million.
• For the year ended December 31, 2024, the pro forma net loss attributable to Fortress improved to a loss of $6.127 million, compared to a reported loss of $45.997 million.

Sentiment

Score: 8

Explanation: The completion of the Checkpoint Therapeutics sale is a highly positive event for Fortress Biotech. It provides immediate cash, potential future milestone payments and royalties, and significantly improves the company's pro forma financial position by reducing losses and generating a substantial gain on deconsolidation. This strategic divestiture appears to strengthen Fortress's balance sheet and financial outlook.

Positives

• Fortress received an immediate cash infusion of approximately $28.0 million, improving its liquidity.
• The company is eligible for additional payments of up to $4.8 million tied to a regulatory milestone, providing potential future upside.
• A Royalty Agreement grants Fortress 2.5% of net sales from certain Checkpoint/Sun Pharma products, establishing a long-term revenue stream.
• The deconsolidation of Checkpoint resulted in a significant pro forma pre-tax gain of $26.6 million.
• Pro forma financial statements show a substantial improvement in net loss attributable to Fortress, turning a Q1 2025 reported loss of $10.584 million into a pro forma gain of $17.131 million.
• The pro forma net loss attributable to Fortress for FY 2024 improved from $45.997 million to $6.127 million, indicating a positive impact on historical performance metrics.

Negatives

• Fortress no longer holds direct ownership or control over Checkpoint Therapeutics, Inc., potentially limiting future direct participation in its growth or product development.
• The additional $4.8 million payment is contingent on a regulatory milestone, which may not be achieved.
• The royalty payments are dependent on the net sales of certain products, introducing market and commercialization risks.

Risks

• Difficulty in predicting the timing or outcome of regulatory approvals or actions.
• Risks related to the non-achievement of the Contingent Value Rights (CVR) milestone, meaning holders may not receive payments.
• The company's growth strategy, financing, and strategic agreements and relationships may face challenges.
• Fortress's need for substantial additional funds and uncertainties relating to future financings.
• Risks in identifying, acquiring, closing, and integrating product candidates successfully and on a timely basis.
• Challenges in attracting, integrating, and retaining key personnel.
• Uncertainties related to the early stage of products under development, preclinical, and clinical testing.
• Risks in obtaining regulatory approval for products under development.
• Challenges in successfully commercializing products for which regulatory approval is received or in receiving royalties/distributions from third parties.
• Difficulties in securing and maintaining third-party manufacturing, marketing, and distribution for products and product candidates.
• Impact of government regulation, patent and intellectual property matters, and competition.

Future Outlook

Fortress Biotech anticipates receiving up to an additional $4.8 million upon the achievement of a regulatory milestone related to Contingent Value Rights. Furthermore, the company expects to receive ongoing quarterly cash payments representing 2.5% of net sales from certain products previously associated with Checkpoint, now under Sun Pharma, for a specified period. The company's forward-looking statements indicate continued focus on product development, regulatory approvals, and commercialization, while acknowledging risks related to funding, integration of new assets, and market competition.

Industry Context

This transaction represents a strategic divestiture for Fortress Biotech, allowing it to monetize a subsidiary and potentially streamline its operations. In the biotechnology and pharmaceutical industry, such divestitures are common strategies for companies to focus on core assets, reduce operational burn, and generate non-dilutive capital. The involvement of Sun Pharmaceutical Industries, a global pharmaceutical company, highlights the ongoing consolidation and strategic partnerships within the sector, where larger players acquire promising assets or companies to expand their pipelines and market reach. The inclusion of CVRs and royalty agreements is a common mechanism in biotech deals to share future upside and mitigate immediate acquisition costs.

Related Party Transactions

• The transaction involves the sale of Checkpoint Therapeutics, Inc., a subsidiary of Fortress Biotech, Inc., to Sun Pharmaceutical Industries, Inc., which is a related party transaction in the context of deconsolidation.

Stakeholder Impact

• **Shareholders:** The transaction provides immediate cash and potential future revenue streams, which could positively impact shareholder value by improving the company's financial health and reducing losses. The gain on deconsolidation and improved pro forma net income are favorable.
• **Employees:** The document does not specify the impact on employees of Checkpoint Therapeutics or Fortress Biotech, but typically, employees of a divested subsidiary transition to the acquiring company.
• **Customers:** Customers of Checkpoint's products will now be served by Sun Pharmaceutical Industries, Inc., potentially leading to changes in product support or distribution, though the document does not detail this.
• **Creditors:** The improved financial position and liquidity from the cash proceeds could enhance Fortress Biotech's ability to meet its financial obligations, potentially benefiting creditors.
• **Suppliers:** No direct impact on suppliers is mentioned, but changes in Checkpoint's operations under Sun Pharma could affect its supplier relationships.

Next Steps

• Fortress Biotech will continue to be eligible for up to an additional $4.8 million upon the achievement of a regulatory milestone associated with the Contingent Value Rights (CVRs).
• Fortress Biotech is eligible to receive quarterly cash payments of 2.5% of net sales of certain products of Checkpoint and Sun Pharma for a specified time period.
• The company will continue to manage its remaining product candidates and operations, subject to the risks outlined in the forward-looking statements.

Key Dates

Recommendation

Keywords

Fortress Biotech, Checkpoint Therapeutics, Sun Pharmaceutical Industries, Merger, Acquisition, Divestiture, Biotechnology, Pharmaceuticals, SEC Filing, 8-K, Contingent Value Rights, Royalty Agreement, Deconsolidation, Financial Statements, Pro Forma, FBIO, FBIOP